Omeprazole Increases the Efficacy of Acyclovir Against Herpes Simplex Virus Type 1 and 2

Abstract

Omeprazole was shown to improve the anti-cancer effects of the nucleoside analogue 5-fluorouracil. Here, we combined omeprazole with the antiviral nucleoside analogues ribavirin and acyclovir. Omeprazole did not affect the antiviral effects of ribavirin in non-toxic concentrations up to 80 μg/mL but increased the acyclovir-mediated effects on herpes simplex virus 1 and 2 (HSV-1 and -2) replication in a dose-dependent manner. Omeprazole alone reduced HSV-1 and -2 titers [but not HSV-induced formation of cytopathogenic effects (CPE)] at concentrations ≥40 μg/mL. However, it exerted substantially stronger effects on acyclovir activity and also increased acyclovir activity at lower concentrations that did not directly interfere with HSV replication. Omeprazole 80 μg/mL caused a 10.8-fold (Vero cells) and 47.7-fold (HaCaT cells) decrease of the acyclovir concentrations that reduced HSV-1-induced CPE formation by 50% (IC50). In HSV-2-infected cells, omeprazole 80 μg/mL reduced the acyclovir IC50 by 7.3- (Vero cells) and 12.9-fold (HaCaT cells). In HaCaT cells, omeprazole 80 μg/mL reduced the HSV-1 titer in the presence of acyclovir 1 μg/mL by 1.6 × 105-fold and the HSV-2 titer in the presence of acyclovir 2 μg/mL by 9.2 × 103-fold. The proton pump inhibitors pantoprazole, rabeprazole, lansoprazole, and dexlansoprazole increased the antiviral effects of acyclovir in a similar fashion as omeprazole, indicating this to be a drug class effect. In conclusion, proton pump inhibitors increase the anti-HSV activity of acyclovir and are candidates for antiviral therapies in combination with acyclovir, in particular for topical preparations for the treatment of immunocompromised individuals who are more likely to suffer from severe complications.

Is SARS-CoV-2 an Etiologic Agent or Predisposing Factor for Oral Lesions in COVID-19 Patients? A Concise Review of Reported Cases in the Literature

“…They have been suggested as treatment options and conversely as risk factors [ 42 ] for COVID-19. However, there are studies that support their inhibitory effects on infectious agents that are frequently found in COVID-19 coinfections like HSV-1/ HSV-2 [ 43 ] and Candida albicans [ 44 ]. Whether the use of these drugs is beneficial or detrimental to COVID-19 patients needs further investigation.…”

An Updated Overview of Herpes Simplex Virus-1 Infection: Insights from Origin to Mitigation Measures

“…Besides, Omeprazole was found to increase the anti-cancer effect of nucleoside analog 5-fluorouracil without affecting ribavirin in nontoxic concentration (up to 80 mg/mL). Instead, it enhances the acyclovir-mediated effect on HSV-1 & 2 [155]. Moreover, a newly synthesized compound 2pyrimidyl benzothiazole derivatives exhibit antiviral activities and inhibitory effect on Hsp90α protein.…”

Antiviral Drug Delivery System for Enhanced Bioactivity, Better Metabolism and Pharmacokinetic Characteristics

“…96 (6) 1 AvDs exhibited anti-HSV effects. NA-AvD acyclovir 88 was activated by viral thymidine kinase and then di-and tri-phosphorylated by cellular kinases. The active tri-phosphorylated forms of acyclovir specifically interfered with viral DNA polymerase and caused chain termination.…”

“…The active tri-phosphorylated forms of acyclovir specifically interfered with viral DNA polymerase and caused chain termination. 88…”